PORT-77

Portal Therapeutics, Inc. · Phase 2 active Small molecule

At a glance

Generic name	PORT-77
Sponsor	Portal Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria (PHASE2)
Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PORT-77 CI brief — competitive landscape report
PORT-77 updates RSS · CI watch RSS
Portal Therapeutics, Inc. portfolio CI